Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Orvain, Corentin  [Clear All Filters]
2016
Orvain C, Beloncle F, Hamel J-F, Thépot S, Mercier M, Kouatchet A, Farhi J, François S, Guardiola P, Asfar P, et al. Different Impact of the Number of Organ Failures and Graft-Versus-Host Disease on the Outcome of Allogeneic Stem Cell Transplantation Recipients Requiring Intensive Care. Transplantation. 2016.
2018
Bouvier A, Ribourtout B, François S, Orvain C, Paz DLuque, Beucher A, Guérard A, Guardiola P, Ugo V, Blanchet O, et al. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2018.
Cottin L, Riou J, Boyer F, Bouvier A, Zannetti A, Blouet A, Truchan-Graczyk M, Jouanneau-Courville R, Beucher A, Ribourtout B, et al. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells Mol Dis. 2018;75:35-40.
2019
Bazarbachi A, Boumendil A, Finel H, Castagna L, Dominietto A, Blaise D, Diez-Martin JL, Tischer J, Gulbas Z, Wallet HL, et al. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol. 2019.
2021
Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Early Post-Transplant Serum Ferritin Levels Predict Survivals in Recipients of Haploidentical Stem Cell Transplantation Using PTCY as GVHD Prophylaxis. Transplant Cell Ther. 2021.
Jullien M, Orvain C, Berceanu A, Couturier M-A, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Klemencie M, Schmidt A, et al. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. Cancer Med. 2021.
Guillaume T, Thépot S, Peterlin P, Ceballos P, Le Bourgeois A, Garnier A, Orvain C, Giltat A, François S, Le Bris Y, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome. Transplant Cell Ther. 2021.
Lacombe V, Gomes CNunes, Robin J-B, Thépot S, François S, Cottin L, Ugo V, Dieu X, Abgueguen P, Daniel V, et al. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. Eur J Haematol. 2021.
2023
Rey G, Daguenet E, Bonjean P, Devillier R, Fegueux N, Forcade E, Srour M, Chevallier P, Robin M, Suarez F, et al. Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC. Bone Marrow Transplant. 2023.
Vély A, Couturier M-A, Delepine P, Le Calloch R, Ertault M, Gastinne T, Plichon C, Lebreton A, Lester M-A, Larhantec G, et al. Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma. Leuk Lymphoma. 2023:1-10.
Griffin M, Eikema D-J, Verheggen I, Kulagin A, Tjon JM-L, Fattizzo B, Ingram W, Zaidi U, Desnica L, Giammarco S, et al. SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria. Haematologica. 2023.
2024
Lacan C, Lambert J, Forcade E, Robin M, Chevallier P, Loron S, Bulabois C-E, Orvain C, Ceballos P, Daguindau E, et al. Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry. J Hematol Oncol. 2024;17(1):2.